|
GENOUS™ SUCCESS STORY
A New Life: The Fight Against Non-Small Cell Lung Cancer (NSCLC)
CHALLENGE
The presence of brain metastases and the discovery of ALK fusions means that standard treatments are no longer effective. The challenge is to find targeted treatments that can control the cancer, and even provide long-term control.
Diagnosed with non-small cell lung cancer (NSCLC) and brain metastases 12 years ago, the woman – then 50 – faced a dire prognosis of just three months to live. Despite treatment, her cancer progressed, and she needed a new, more targeted approach to improve her chances of survival.
PRECISION CANCER SOLUTIONS
The treatment team performed detailed genetic testing using next-generation sequencing technology on 58 cancer genes, combined with fluorescence in situ hybridization (FISH). They identified an ALK fusion - a mutation that can be targeted by new generation ALK inhibitors. Oncompass (Genomate) analyzed the genetic data and identified LDK378 (Ceritinib), a new generation ALK inhibitor that is in clinical trials and is a promising treatment option. The Molecular Tumor Board facilitated the patient's enrollment in a clinical trial in Malaga, Spain, where she could access this innovative therapy.
THE RIGHT DRUG. THE FIRST TIME. EVERYTIME
The patient had a complete response to Ceritinib, remained on the drug for six years, and had complete control of the cancer. The patient is now tumor-free, and continues treatment with another targeted therapy, Lorlatinib. For the treatment team, this means:
Higher success rate
Make decisions faster
Limit guesswork and side effects
Give patients the best treatment opportunities
OUTCOMES AND IMPACT OF TARGETED THERAPY